EGFR and head and neck cancer: In the current study, the researchers found that Axitinib had the potential to target epidermal growth factor receptor (EGFR) and was associated with improved survival in patients with heavily pretreated head and neck cancer.41 Subsequently, we performed a drug susceptibility analysis of PLAU and found that Dasatinib, Midostaurin, and Palbociclib had the most relevant potential effects in the PLAU-high HNSCC subclass.